aeolus pharmaceuticals inc
(AOLS:OTC US)

Last $0.42 USD

Change Today +0.001 / 0.24%

Volume 48.2K

AOLS On Other Exchanges

Symbol

Exchange

AOLS:US

OTC US

IC9A:GR

Berlin

As of 8:10 PM 05/17/13 All times are local (Market data is delayed by at least 15 minutes).

aeolus pharmaceuticals inc (AOLS) Snapshot

Open $0.41		Previous Close $0.42
Day High $0.42		Day Low $0.39
52 Week High 03/1/13 - $0.48		52 Week Low 05/23/12 - $0.21
Market Cap 56.5M		Average Volume 10 Days 39.3K
EPS TTM $-0.12		Shares Outstanding 134.6M
EX-Date --		P/E TM --
Dividend --		Dividend Yield --

Current Stock Chart for AEOLUS PHARMACEUTICALS INC (AOLS)

AOLS:US Historical Stock Quote
AOLS:US Advanced Stock Chart

Related News

No related news articles were found.

aeolus pharmaceuticals inc (AOLS) Related Businessweek News

No Related Businessweek News Found

aeolus pharmaceuticals inc (AOLS) Details

Aeolus Pharmaceuticals, Inc., a biotechnology company, engages in the development of a platform of novel compounds that protect against radiological and chemical threats and for use in oncology. The company develops a class of catalytic antioxidant compounds as a medical countermeasure against biological, chemical, and radiological weapons, as well as for diseases and disorders of the central nervous system, respiratory system, autoimmune system, and oncology. Its lead compound, AEOL 10150, which completed 2 Phase I clinical trials is developed against the pulmonary sub-syndrome of acute radiation syndrome, as well as the gastrointestinal sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure (MCM) for exposure to chemical vesicants, such as chlorine gas, sulfur mustard gas, and nerve agents. The company also develops AEOL 11207 for the treatment of epilepsy and Parkinson’s disease; and AEOL 10171 as a potential MCM for acute radiation syndrome. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

Detailed AOLS:US Company Description...

www.aeoluspharma.com

5 Employees
Last Reported Date: 02/20/13

Founded in 1994

Latest 10-K

Latest 10-Q

More AOLS SEC Filings...

aeolus pharmaceuticals inc (AOLS) Top Compensated Officers

Mr. John L. McManus

Chief Executive Officer and President

Age: 48

Total Annual Compensation: $409.0K

Mr. Russell L. Skibsted

Chief Financial Officer, Principal Accounting...

Age: 53

Total Annual Compensation: $255.6K

Dr. Brian J. Day Ph.D.

Chief Scientific Officer

Age: 52

Total Annual Compensation: --

Executives, Board Directors

Compensation as of Fiscal Year 2012.

aeolus pharmaceuticals inc (AOLS) Key Developments

Aeolus Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2013

May 15 13

Aeolus Pharmaceuticals Inc. reported unaudited consolidated earnings results for the second quarter and six months ended March 31, 2013. For the quarter, revenue was $0.859 million against $2.231 million a year ago. Loss from operations was $0.762 million against $0.561 million a year ago. Net loss was $5.782 million or $0.06 per diluted share against net income of $2.763 million or $0.00 per diluted share a year ago. For the six months, revenue was $2.201 million against $4.446 million a year ago. Loss from operations was $1.245 million against $1.272 million a year ago. Net loss was $1.755 million or $0.03 per diluted share against net income of $5.740 million or $0.01 per diluted share a year ago.

Aeolus Pharmaceuticals Inc. Announces Board Changes

May 10 13

Aeolus Pharmaceuticals Inc. announced that on May 8, 2013, each of Joseph J. Krivulka, Michael E. Lewis, Ph.D. and Peter D. Suzdak, Ph.D. notified the company of his resignation from the Board of Directors of Aeolus and from all committee memberships, as applicable. The decision of each of Mr. Krivulka, Dr. Lewis and Dr. Suzdak to resign from the Board was not due to any disagreement with Aeolus on any matter relating to Aeolus' operations, policies or practices. Concurrently with the resignations of Mr. Krivulka, Dr. Lewis and Dr. Suzdak from the Board, the Board appointed John Clerici, Mitchell D. Kaye and Jeffrey A. Scott, M.D. to serve as directors of the Board, effective May 8, 2013. Each of Mr. Clerici, Mr. Kaye and Dr. Scott will serve until such time as his respective successor is duly elected and qualified or until his earlier resignation or removal. John M. Clerici is a founding Principal of Tiber Creek Partners, LLC. Mitchell D. Kaye, J.D. is the Founder of MedClaims Liaison, LLC. Jeffrey A. Scott, M.D. currently is General Manager/Senior Vice President for P4 Healthcare.

Aeolus Pharmaceuticals Inc. Presents at Taglich Brothers 10th Annual Small Cap Equity Conference, May-07-2013 02:00 PM

Apr 19 13

Aeolus Pharmaceuticals Inc. Presents at Taglich Brothers 10th Annual Small Cap Equity Conference, May-07-2013 02:00 PM. Venue: New York Athletic Club, 180 Central Park South (59th street @ 7th Avenue), New York, New York, United States. Speakers: John L. McManus, Chief Executive Officer and President, Russell L. Skibsted, Chief Financial Officer, Principal Accounting Officer, Senior Vice President and Secretary.